[{"id":"50675b6c-a099-4a04-9217-8bea26cfbfcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06026605","created_at":"2023-09-07T16:09:36.545Z","updated_at":"2024-07-02T16:35:03.844Z","phase":"Phase 1","brief_title":"A Dose Escalation and Dose Expansion Trial of WTX212A in the Treatment of Patients With Advanced Malignant Tumors","source_id_and_acronym":"NCT06026605","lead_sponsor":"Zhejiang University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WTX212"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 08/25/2023","start_date":" 08/25/2023","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2024-05-14"},{"id":"e93517f6-aee4-46a7-9ae6-62f1d5bba6f6","acronym":"Reboot-105","url":"https://clinicaltrials.gov/study/NCT06106152","created_at":"2024-03-26T18:39:47.230Z","updated_at":"2024-07-02T16:35:12.830Z","phase":"Phase 1","brief_title":"WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody","source_id_and_acronym":"NCT06106152 - Reboot-105","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WTX212"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/05/2023","start_date":" 12/05/2023","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-26"}]